CLINICAL TRIALS PROFILE FOR CC-99677
✉ Email this page to a colleague
Clinical Trials for CC-99677
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03554993 ↗ | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects | Completed | Celgene | Phase 1 | This is a phase 1, randomized, single-center, 3-part, FIH study to assess the safety, tolerability, pharmacokinetics (PK, or how the drug behaves in the body), and pharmacodynamics (PD, or what the drug does to the body) of single and multiple doses of CC-99677 and to characterize the effect of food on the single-dose PK of CC-99677 in healthy adult subjects. |
| NCT04268394 ↗ | A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677 | Completed | Celgene | Phase 1 | It is a phase 1, open-label, single-center, three-part study to assess the safety, tolerability, and pharmacokinetics of multiple doses of CC-99677 administered alone or in combination with either methotrexate and sulfasalazine; itraconazole, rifampin, midazolam, or a cocktail of digoxin, metformin, and rosuvastatin in healthy subjects |
| NCT04718636 ↗ | A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants | Completed | Celgene | Phase 1 | The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC). |
| NCT04947579 ↗ | A Study of CC-99677 in Participants With Active Ankylosing Spondylitis | Recruiting | Celgene | Phase 2 | This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period. |
| NCT04958291 ↗ | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants. | Not yet recruiting | Celgene | Phase 1 | This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and pharmacogenomics (PG) of multiple doses of CC-99677 in healthy Japanese adult participants. This study will be placebo-controlled to appropriately characterize the safety and tolerability of CC-99677. |
| NCT05284890 ↗ | A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants | Not yet recruiting | Bristol-Myers Squibb | Phase 1 | The purpose of the study is to characterize the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of [14C] CC-99677. |
| NCT05445440 ↗ | A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine | Not yet recruiting | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CC-99677
Condition Name
Clinical Trial Locations for CC-99677
Trials by Country
Clinical Trial Progress for CC-99677
Clinical Trial Phase
Clinical Trial Sponsors for CC-99677
Sponsor Name
